“…Because prostacyclin receptor is expressed in many tissues such as aorta, lung, atrium, ventricle, and kidney (20), and because PG transporter (12) does not mediate the vascular clearance of prostacyclin, the endogenous prostacyclin synthe- sis inhibitory peptide may have inhibitory effects against widespread biological actions of prostacyclin. This peptide also may counteract a biological action of AA such as inhibition of voltage-gated Ca 2ϩ current, because a major acting site of coupling factor 6 is the inhibition of AA release from the plasma membrane.…”